Kyle Smoot

498 total citations
22 papers, 321 citations indexed

About

Kyle Smoot is a scholar working on Pathology and Forensic Medicine, Oncology and Neurology. According to data from OpenAlex, Kyle Smoot has authored 22 papers receiving a total of 321 indexed citations (citations by other indexed papers that have themselves been cited), including 12 papers in Pathology and Forensic Medicine, 9 papers in Oncology and 7 papers in Neurology. Recurrent topics in Kyle Smoot's work include Multiple Sclerosis Research Studies (12 papers), Polyomavirus and related diseases (9 papers) and Peripheral Neuropathies and Disorders (3 papers). Kyle Smoot is often cited by papers focused on Multiple Sclerosis Research Studies (12 papers), Polyomavirus and related diseases (9 papers) and Peripheral Neuropathies and Disorders (3 papers). Kyle Smoot collaborates with scholars based in United States, Canada and Switzerland. Kyle Smoot's co-authors include Richard Kryscio, Wayne A. Cass, Don M. Gash, Stanley Cohan, Elisabeth B. Lucassen, Pavle Repovic, Jonathan Calkwood, Jason P. Mendoza, Harold Moses and Carlo Tornatore and has published in prestigious journals such as Journal of Neuroscience, SHILAP Revista de lepidopterología and Neurology.

In The Last Decade

Kyle Smoot

21 papers receiving 312 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Kyle Smoot United States 8 146 102 94 72 63 22 321
Jeff Gamez United States 8 152 1.0× 32 0.3× 57 0.6× 46 0.6× 94 1.5× 9 398
Sam Horng United States 8 51 0.3× 51 0.5× 55 0.6× 43 0.6× 114 1.8× 12 410
Marco Turatti Italy 13 186 1.3× 21 0.2× 99 1.1× 36 0.5× 63 1.0× 21 283
Jürgen A. Hampl Germany 9 62 0.4× 25 0.2× 42 0.4× 34 0.5× 57 0.9× 17 267
Jan Mendelt Tillema United States 5 262 1.8× 27 0.3× 231 2.5× 29 0.4× 38 0.6× 6 352
Vincent Desportes France 9 80 0.5× 44 0.4× 95 1.0× 11 0.2× 109 1.7× 15 323
Mareike Schimmel Germany 8 206 1.4× 41 0.4× 310 3.3× 43 0.6× 46 0.7× 28 424
Wiebke Stark Germany 9 266 1.8× 20 0.2× 127 1.4× 70 1.0× 43 0.7× 13 353
Michelle Naughton United Kingdom 8 104 0.7× 29 0.3× 32 0.3× 21 0.3× 63 1.0× 10 227

Countries citing papers authored by Kyle Smoot

Since Specialization
Citations

This map shows the geographic impact of Kyle Smoot's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Kyle Smoot with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Kyle Smoot more than expected).

Fields of papers citing papers by Kyle Smoot

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Kyle Smoot. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Kyle Smoot. The network helps show where Kyle Smoot may publish in the future.

Co-authorship network of co-authors of Kyle Smoot

This figure shows the co-authorship network connecting the top 25 collaborators of Kyle Smoot. A scholar is included among the top collaborators of Kyle Smoot based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Kyle Smoot. Kyle Smoot is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Mao‐Draayer, Yang, Amit Bar‐Or, John Foley, et al.. (2024). Real-World Safety and Effectiveness of Dimethyl Fumarate in Patients with MS: Results from the ESTEEM Phase 4 and PROCLAIM Phase 3 Studies with a Focus on Older Patients. Advances in Therapy. 42(1). 395–412. 2 indexed citations
2.
Smoot, Kyle, et al.. (2024). Impact of oral melatonin supplementation on urine and serum melatonin concentrations and quality-of-life measures in persons with relapsing multiple sclerosis. Multiple Sclerosis and Related Disorders. 90. 105799–105799. 2 indexed citations
3.
4.
Smoot, Kyle, et al.. (2023). Evaluating the efficacy and safety of transitioning patients with multiple sclerosis from natalizumab to ocrelizumab (OCTAVE). Multiple Sclerosis Journal. 29(8). 956–966. 3 indexed citations
5.
Cohan, Stanley, Barry Hendin, Anthony T. Reder, et al.. (2021). Interferons and Multiple Sclerosis: Lessons from 25 Years of Clinical and Real-World Experience with Intramuscular Interferon Beta-1a (Avonex). CNS Drugs. 35(7). 743–767. 1 indexed citations
6.
Budhram, Adrian, et al.. (2021). Vessel Wall Enhancement in Unilateral Primary Angiitis of the Central Nervous System. Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques. 49(3). 423–425. 1 indexed citations
7.
Smoot, Kyle, et al.. (2021). Clinical outcomes of patients with multiple sclerosis treated with ocrelizumab in a US community MS center: an observational study. SHILAP Revista de lepidopterología. 3(2). e000108–e000108. 20 indexed citations
8.
Bowen, James D., et al.. (2020). COVID-19 in MS. Neurology Neuroimmunology & Neuroinflammation. 7(5). 28 indexed citations
9.
Cohan, Stanley, et al.. (2020). Sphingosine-1-Phosphate: Its Pharmacological Regulation and the Treatment of Multiple Sclerosis: A Review Article. Biomedicines. 8(7). 227–227. 42 indexed citations
10.
Cohan, Stanley, et al.. (2019). Reducing return of disease activity in patients with relapsing multiple sclerosis transitioned from natalizumab to teriflunomide: 12-month interim results of teriflunomide therapy. Multiple Sclerosis Journal - Experimental Translational and Clinical. 5(1). 2453244586–2453244586. 6 indexed citations
11.
Smoot, Kyle. (2019). Utilization, safety, and tolerability of ocrelizumab: year 2 data from the Providence Ocrelizumab Registry. 1 indexed citations
12.
Smoot, Kyle, et al.. (2019). Evaluating the Efficacy and Safety of Transitioning Patients from Natalizumab to Ocrelizumab (OCTAVE) (P3.2-056). Neurology. 92(15_supplement). 3 indexed citations
13.
Cohan, Stanley, Harold Moses, Jonathan Calkwood, et al.. (2018). Clinical outcomes in patients with relapsing-remitting multiple sclerosis who switch from natalizumab to delayed-release dimethyl fumarate: A multicenter retrospective observational study (STRATEGY). Multiple Sclerosis and Related Disorders. 22. 27–34. 42 indexed citations
14.
Cohan, Stanley, Kyle Smoot, Robert B. Garland, et al.. (2018). Outcomes of Stable Multiple Sclerosis Patients Staying on Initial Interferon Beta Therapy Versus Switching to Another Interferon Beta Therapy: A US Claims Database Study. Advances in Therapy. 35(11). 1894–1904. 5 indexed citations
15.
Smoot, Kyle, et al.. (2017). Three-year clinical outcomes of relapsing multiple sclerosis patients treated with dimethyl fumarate in a United States community health center. Multiple Sclerosis Journal. 24(7). 942–950. 20 indexed citations
16.
Smoot, Kyle, et al.. (2016). Return to Play After Exertional Rhabdomyolysis. Journal of Athletic Training. 51(5). 406–409. 10 indexed citations
17.
18.
Cook, James R., Leenhapong Navaravong, Robert A. Levine, et al.. (2012). T-wave inversion and diastolic dysfunction in patients with electrocardiographic left ventricular hypertrophy. Journal of Electrocardiology. 45(6). 764–769. 8 indexed citations
19.
Smith, Charles D., Ashley Walton, John T. Slevin, et al.. (2007). Validation studies of the human movement analysis panel for hand/arm performance. Journal of Neuroscience Methods. 165(2). 287–296. 4 indexed citations
20.
Cass, Wayne A., et al.. (1997). GDNF Protection against 6-OHDA: Time Dependence and Requirement for Protein Synthesis. Journal of Neuroscience. 17(18). 7111–7118. 113 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Jeff Gamez Breakdown of academic impact, for papers by Sam Horng Breakdown of academic impact, for papers by Marco Turatti Breakdown of academic impact, for papers by Jürgen A. Hampl Breakdown of academic impact, for papers by Jan Mendelt Tillema Breakdown of academic impact, for papers by Vincent Desportes Breakdown of academic impact, for papers by Mareike Schimmel Breakdown of academic impact, for papers by Wiebke Stark Breakdown of academic impact, for papers by Michelle Naughton
Rankless by CCL
2026